StockData
ADMA Biologics, Inc. logo

ADMA Biologics, Inc. (ADMA) stock

ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3028% below fair value
$13.63+0.16 (+1.19%)

Close on Nov 17, 2026Market cap $3.05BP/E 19.5Yield –

ADMA Biologics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

ADMA Biologics's revenue for the twelve months ending Jun 30, 2026 was $512.28M, up 8.0% year over year. For fiscal 2025 it was $510.17M, up 19.6% from the year before. Over ten years it grew 53.2% a year on average. The highest annual figure on record is $510.17M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$510.17M+19.6%
FY2024Dec 31, 2024$426.45M+65.2%
FY2023Dec 31, 2023$258.22M+67.6%
FY2022Dec 31, 2022$154.08M+90.4%
FY2021Dec 31, 2021$80.94M+91.7%
FY2020Dec 31, 2020$42.22M+43.9%
FY2019Dec 31, 2019$29.35M+72.8%
FY2018Dec 31, 2018$16.99M-25.4%
FY2017Dec 31, 2017$22.76M+113.5%
FY2016Dec 31, 2016$10.66M+48.5%
FY2015Dec 31, 2015$7.18M+21.3%
FY2014Dec 31, 2014$5.92M+92.8%
FY2013Dec 31, 2013$3.07M+174.4%
FY2012Dec 31, 2012$1.12M+46.9%
FY2011Dec 31, 2011$761.04K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$124.40M+2.0%
Q1 FY2026Mar 31, 2026$114.49M-0.3%
Q4 FY2025Dec 31, 2025$139.16M+18.4%
Q3 FY2025Sep 30, 2025$134.22M+12.0%
Q2 FY2025Jun 30, 2025$121.98M+13.8%
Q1 FY2025Mar 31, 2025$114.80M+40.2%
Q4 FY2024Dec 31, 2024$117.55M+59.1%
Q3 FY2024Sep 30, 2024$119.84M+78.1%
Q2 FY2024Jun 30, 2024$107.19M+78.3%
Q1 FY2024Mar 31, 2024$81.88M+43.9%
Q4 FY2023Dec 31, 2023$73.90M+47.9%
Q3 FY2023Sep 30, 2023$67.28M+63.7%
Q2 FY2023Jun 30, 2023$60.12M+77.3%
Q1 FY2023Mar 31, 2023$56.91M+95.6%
Q4 FY2022Dec 31, 2022$49.98M+89.4%
Q3 FY2022Sep 30, 2022$41.09M+98.7%
Q2 FY2022Jun 30, 2022$33.91M+90.2%
Q1 FY2022Mar 31, 2022$29.10M+81.3%
Q4 FY2021Dec 31, 2021$26.38M+89.0%
Q3 FY2021Sep 30, 2021$20.68M+101.2%
Q2 FY2021Jun 30, 2021$17.83M+129.0%
Q1 FY2021Mar 31, 2021$16.05M+57.3%
Q4 FY2020Dec 31, 2020$13.96M+15.9%
Q3 FY2020Sep 30, 2020$10.28M+42.3%
Q2 FY2020Jun 30, 2020$7.79M+18.7%
Q1 FY2020Mar 31, 2020$10.20M+189.1%
Q4 FY2019Dec 31, 2019$12.04M+196.7%
Q3 FY2019Sep 30, 2019$7.22M+70.7%
Q2 FY2019Jun 30, 2019$6.56M+40.9%
Q1 FY2019Mar 31, 2019$3.53M-12.7%
Q4 FY2018Dec 31, 2018$4.06M-66.2%
Q3 FY2018Sep 30, 2018$4.23M-10.6%
Q2 FY2018Jun 30, 2018$4.66M+37.0%
Q1 FY2018Mar 31, 2018$4.04M+53.8%
Q4 FY2017Dec 31, 2017$12.00M+260.7%
Q3 FY2017Sep 30, 2017$4.73M+61.0%
Q2 FY2017Jun 30, 2017$3.40M–
Q1 FY2017Mar 31, 2017$2.63M–
Q4 FY2016Dec 31, 2016$3.33M–
Q3 FY2016Sep 30, 2016$2.94M–

More ADMA Biologics figures

See a number that looks wrong?